Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Articles online first > Giornale Italiano di Dermatologia e Venereologia 2020 May 21



Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Giornale Italiano di Dermatologia e Venereologia 2020 May 21

DOI: 10.23736/S0392-0488.20.06654-7


lingua: Inglese

Diagnosis and management of moderate to severe atopic dermatitis in adolescents. A Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists and Public Health (ADOI), the Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), the Italian Society of Pediatric Allergy and Immunology (SIAIP), the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA), and the Italian Society of Pediatric Dermatology (SIDerP)

Piergiacomo CALZAVARA-PINTON 1 , Anna BELLONI FORTINA 2, Domenico BONAMONTE 3, Gian Luigi MARSEGLIA 4, Michele MIRAGLIA DEL GIUDICE 5, Antonino MUSARRA 6, Eustachio NETTIS 7, Iria NERI 8, Cataldo PATRUNO 9, Luca STINGENI 10, Ketty PERIS 11, on behalf of RADAR Group 

1 Clinic of Dermatology, University of Brescia, Brescia, Italy; 2 Pediatric Dermatology, DIMED, University of Padua, Padua, Italy; 3 Section of Dermatology, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy; 4 Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy; 5 Department of Woman and Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy; 6 Allergy Unit, National Healthcare System, Reggio Calabria, Italy; 7 Department of Emergency and Organ Transplantation, School and Chair of Allergology and Clinical Immunology, University of Bari-Aldo Moro, Bari, Italy; 8 Dermatology Unit, Department of Specialistic, Diagnostic and Experimental Medicine, University of Bologna, Bologna, Italy; 9 Dermatology Unit, Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy; 10 Section of Clinical Allergological Venereological Dermatology, Department of Medicine, University of Perugia, Perugia, Italy; 11 Dermatology Unit, Catholic University of Rome, and Fondazione Policlinico A. Gemelli - IRCCS, Rome, Italy

Atopic dermatitis (AD) is a chronic inflammatory disease with increasing global incidence, which has a multifactorial pathogenesis and a variable expressivity. Clinical features of AD are different in adults compared to children, but it is well recognized the substantial impact of the disease on patients’ quality of life at any age. Indeed, little is known about AD in adolescence, a period of life generally associated with high psychological burden and vulnerability to depression. Guidelines for the management of AD are available for both children and adults but specific guidelines for the diagnosis and treatment of AD in adolescents are lacking. Seven Italian scientific societies of dermatologists, allergists, and pediatric allergists joined in a specific meeting to provide practical guidance for the diagnosis and management of moderate-to-severe adolescent AD suitable for the Italian clinical practice. Through a modified Delphi procedure, consensus was reached by 59 Italian experts in the management of AD on 20 statements covering five areas of interest about adolescent AD, including disease complexity, burden and social impact, diagnosis and definition of severity, current treatments, and new biologic therapies. This paper reports recommendations for the diagnosis and management of AD specifically in adolescents, pointing out some peculiar clinical features and focusing on the choice of medications. Dupilumab, the first biologic approved for the treatment of adolescents with AD, represents a useful treatment option due to its efficacy and reassuring safety profile.

KEY WORDS: Atopic dermatitis; Adolescents; Diagnosis; Severity assessment; Management; Therapy; Biologics; Dupilumab

inizio pagina